10,13-二甲基-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3,17-二醇 | 521-17-5

• 物质功能分类: 化学试剂 - 有机试剂 - 脂肪醇
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 10,13-二甲基-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3,17-二醇
• 英文名称: androst-5-ene-3β,17β-diol
• 英文别名: 5-androstene-diol；Androst-5-ene-3beta,17beta-diol；10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 521-17-5；1963-03-7；4593-57-1；4593-58-2；14504-94-0；16895-59-3；47122-33-8；64162-67-0；75767-22-5；139973-51-6；151284-19-4
• 化学式: C₁₉H₃₀O₂
• 分子量: 290.446
• InChiKey: QADHLRWLCPCEKT-UHFFFAOYSA-N

物化性质

• 熔点：
  178-182°C
• 比旋光度：
  -52.2 º (c=0.4,2-propanol)
• 沸点：
  428.4±38.0 °C(Predicted)
• 密度：
  1.12±0.1 g/cm3(Predicted)
• 溶解度：
  DMF：25mg/mL； DMSO：15mg/mL； DMSO:PBS (pH 7.2) (1:1)：0.5 mg/ml；乙醇：10mg/mL
• 稳定性/保质期：
  在常温常压下保持稳定，会与氧化剂发生反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  F,T
• 安全说明：
  S24/25
• 危险类别码：
  R60,R61,R11,R19,R38
• 海关编码：
  29061990
• 储存条件：
  密封储存，应存放在阴凉、干燥的仓库中。

SDS

Name:	5-Androstene-3Beta 17Beta-Diol Hydrate 98% Material Safety Data Sheet
Synonym:	Androstenediol; Androst-5-Enediol
CAS:	521-17-5

Section 1 - Chemical Product MSDS Name:5-Androstene-3Beta 17Beta-Diol Hydrate 98% Material Safety Data Sheet
Synonym:Androstenediol; Androst-5-Enediol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
521-17-5	5-Androstene-3Beta,17Beta-Diol Hydrate	98	208-306-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
Adverse reproductive effects have been reported in animals.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Hormones and antibiotics room.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 521-17-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 179.00 - 182.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C19H30O2.xH2O
Molecular Weight: 290.44

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 521-17-5: BV8091000 LD50/LC50:
Not available.
Carcinogenicity:
5-Androstene-3Beta,17Beta-Diol Hydrate - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 521-17-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 521-17-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 521-17-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途：用于制备甾体激素和避孕药的中间体。

反应信息

• 作为反应物：
  描述：

  10,13-二甲基-2,3,4,7,8,9,11,12,14,15,16,17-十二氢-1H-环戊二烯并[a]菲-3,17-二醇 在 barium permanganate 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以60%的产率得到3,17-Dioxo-androsten-5
  参考文献：
  名称：

  高锰酸钡，Ba（MnO 4）2，一种在质朴和非水条件下使用的通用轻度氧化剂

  摘要：

  高锰酸钡是一种易于制备，稳定且用途广泛的氧化试剂。用这种试剂，将不同类型的伯羟基和仲羟基化合物转化为它们的羰基衍生物。醛可以转化为其羧酸。氯化苄和溴化物被转化为醛和羧酸。苄基羰基化合物的氨基脲和2,4-二硝基苯肼衍生物选择性地进行碳-氮键裂解，并生成预期的羰基化合物。对苯二酚转化为对苯二酚-苯并胍基酮和芳族胺形成其偶氮化合物。蒽和菲产生它们的9,10-醌。二苯基乙炔和反式二苯乙烯生成苯甲酰，而苯乙烯生成苯甲醛。发生仲苄基碳氢键的选择性氧化，并以高收率生产相应的羰基化合物。

  DOI：

  10.1016/s0040-4020(01)87874-1

文献信息

• Novel Series of Imidazolyl Substituted Steroidal and Indan-1-One Derivatives
  申请人：Bansal Ranju

  公开号：US20090137541A1

  公开（公告）日：2009-05-28

  The present invention provides a novel series of imidazolyl substituted steroidal and indan-1-one derivatives and salts thereof having the following general structural formulae (A and B)

  本发明提供了一种新的咪唑基取代类固醇和茚环-1-酮衍生物及其盐，其具有以下一般结构式（A和B）。
• Cardwell et al., Journal of the Chemical Society, 1953, p. 361,379
  作者：Cardwell et al.

  DOI：——

  日期：——
• NOVEL SERIES OF IMIDAZOLYL SUBSTITUTED STEROIDAL AND INDAN-1-ONE DERIVATIVES
  申请人：Council of Scientific and Industrial Research

  公开号：EP1934241B1

  公开（公告）日：2012-11-14
• US7375098B2
  申请人：——

  公开号：US7375098B2

  公开（公告）日：2008-05-20
• US8361996B2
  申请人：——

  公开号：US8361996B2

  公开（公告）日：2013-01-29